Allied Signs LOI with Asian Company to Form JV to Expand into the Asian CBD Cosmetic Market

大麻公司Allied与香港CBD Group Asia成立合资公司,进军亚洲CBD化妆品市场

2019-09-23 13:00:00 CFN Media Group

本文共2106个字,阅读需6分钟

Allied Corp.   – an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues – is pleased to announce that it will be expanding its natural health products into the cannabidiol cosmetic market in Asia with Hong Kong-based CBD Group Asia Limited . On September 11, 2019, Allied signed a letter of intent to form a joint venture to leverage CBD Group Asia’s capabilities to distribute Allied’s CBD-based cosmetics and natural health products in China, Hong Kong and throughout Asia. Under the agreement, Allied and CBD Group Asia will form a joint venture corporation (“JV CO”) that will enable Allied and CBD Group Asia to split the net income from the sales of Allied’s natural health products in the Asian market. Allied will fund the initial launch of JV Co with USD $200,000 which will be reimbursed out of first revenue, after which the revenue will be split 50:50. Allied and CBD Group Asia joint venture is subject to the parties entering into a definitive joint venture agreement. The launch in early September 2019 of Tactical Relief™ in the United States by an affiliate of Allied caught the attention of CBD Group Asia, which offered Allied an expansion of distribution into Asia. Allied intends to develop a natural health hemp-derived CBD infused cosmetic brand for the Asian market, Asian Life. The first products will be under the product name that is the Mandarin symbol for “living life alive.” “I am beyond pleased to announce that Allied is in the process of becoming a first mover in the Asian CBD market. We feel that Allied’s natural health products have promising potential in this market, creating additional important revenue potential for Allied,” said Calum Hughes, CEO of Allied Corp. CBD Group Asia’s principals boast over ten years of experience specializing in the importation and customization of premium Canadian consumer packaged goods (CPGs) for the Chinese marketplace. CBD Group Asia’s management team has previously distributed premium Canadian CPGs into China’s largest retail chains and C-stores, including RT-Mart International Ltd and Carrefour SA. RT-Mart alone operates over 484 retail locations covering 233 cities and 29 provinces in China, generating $20 billion USD in sales in 2018. By 2024, the CBD market in China alone is forecasted to be worth USD $15 billion, according to Hong Kong-based investment company Regent Pacific Group, citing the beauty and wellness sector as the main driver. “We are delighted to partner with Allied Corp. to aid their successful entry into Asia alongside us as Joint Venture partners. We feel Allied’s product portfolio fits Asian consumers’ requirements perfectly. We see a huge opportunity to market and brand Allied’s products into one of the largest cosmetics market in the world. We look forward to making this arrangement a huge success alongside Allied and their team,” said James Foster, CEO of CBD Group Asia. About Allied Corp. Allied Corp. is an international medical cannabis production company with a mission to address today’s medical issues by researching, creating and producing targeted cannabinoid health solutions. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products. About CBD Asia Group CBD Group Asia (“CGA”) is opening up avenues of growth in embryonic cannabidiol (CBD) markets emerging in Asia. CGA is positioning itself as a conduit in this region through investment in Asian CBD hyper growth stories and distribution of growth orientated North American based CBD brands. CGA is utilising its management team’s decades-long investment, sales and marketing experience of consumer products in Asia in order to grow and expand within the Asian CBD sector. Media Contact: [email protected] Investor Relations: Anthony Zelen [email protected] +1-778-388-5258 Forward-Looking Statements: This news release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or future performance. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as “anticipate”, “become”, “objective”, “may”, “will”, “might”, “should”, “could”, “can”, “intend”, “expect”, “believe”, “estimate”, “predict”, “potential”, “plan”, “is designed to”, “project”, “continue”, or similar expressions suggest future outcomes or the negative thereof or similar variations. Such forward-looking statements include, but are not limited to, that the company will be able to enter into a definitive joint venture agreement with CGA, that the joint venture will be successful and that the joint venture will be successful in selling the proposed natural health hemp-derived CBD infused cosmetic brand Asian Life throughout China, Hong Kong and Asia. We are also subject to various additional risks as described in our SEC filings at www.SEC.gov. Forward-looking statements are based on management’s current expectations and may materially differ from actual results. Further, such forward-looking statements are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Allied Corp .–一家国际医用大麻公司,专注于创建和提供针对性的大麻健康解决方案,以解决当今的医疗问题。该公司高兴地宣布,将与总部位于香港的 CBD Group Asia Limited 共同将其天然保健产品拓展至亚洲的大麻化妆品市场。2019年9月11日, Allied 签署意向书,成立合资公司,利用 CBD Group Asia 在中国、香港和亚洲各地经销 Allied 基于 CBD 的化妆品和天然保健品的能力。 根据该协议, Allied 和 CBD Group Asia 将成立一家合资公司(“ JVCO ”),使 Allied 和 CBD Group Asia 能够将 Allied 天然保健品在亚洲市场的销售净收入分割开来。Allied 将为合资公司的首次启动提供200,000美元的资金,这些资金将从第一笔收入中偿还,此后收入将按50:50分割。Allied 和 CBD Group Asia 合营企业须由双方订立最终合营协议。 联合公司的一家附属公司于2019年9月初在美国启动了战术救援™计划,引起了 CBD 亚洲集团的注意, CBD 亚洲集团向联合公司提供了向亚洲扩张的分销渠道。联合公司打算开发一个天然的健康血红素衍生的 CBD 注入化妆品品牌的亚洲市场,亚洲生活。第一批产品将以产品名称命名,这是“活生生”的国语符号。 “我非常高兴地宣布, Allied 正在成为亚洲 CBD 市场的先行者。我们认为, Allied 的天然保健品在这个市场上有很大的潜力,为 Allied 创造了额外的重要收入潜力,” Allied Corp 首席执行官 Calum Hughes 说。 CBD 集团的亚洲负责人拥有十多年的经验,专门为中国市场进口和定制加拿大优质消费品。CBD 集团( CBD Group Asia )的管理团队此前已向中国最大的零售连锁店和 C-store 分销加拿大优质消费品,其中包括 RT-Mart International Ltd 和家乐福( Carrefour SA )。仅 RT-Mart 就经营着超过484个零售门店,覆盖中国233个城市和29个省份,2018年销售额达200亿美元。 总部位于香港的投资公司 Regent Pacific Group 预计,到2024年,仅中国的 CBD 市场就将价值150亿美元,其中以美容和健康行业为主要驱动力。 “我们很高兴与 Allied Corp .合作,帮助他们作为合资伙伴成功进入亚洲。我们认为, Allied 的产品组合完全符合亚洲消费者的要求。我们看到了一个巨大的机会,市场和品牌联合的产品,成为世界上最大的化妆品市场之一。我们期待着与 Allied 及其团队一起,使这一安排取得巨大成功,” CBD 集团亚洲首席执行官詹姆斯•福斯特( James Foster )表示。 关于 Allied 公司。 Allied Corp .是一家国际医用大麻生产公司,其使命是通过研究、创造和生产有针对性的大麻健康解决方案来解决当今的医疗问题。Allied Corp .采用循证科学方法,通过尖端的医药研发、基于植物的创新生产和治疗产品的独特开发,使这一使命成为可能。 关于 CBD 亚洲集团 CBD 集团亚洲(以下简称“ CGA ”)正在开拓亚洲新兴的胚胎肠衣( CBD )市场的增长途径。通过对亚洲 CBD 超增长故事的投资和以北美为基地的 CBD 品牌的分销, CGA 将自己定位为该地区的渠道。CGA 正在利用其管理团队在亚洲数十年的消费品投资、销售和营销经验,以便在亚洲 CBD 领域内增长和扩张。 媒体联系人: [受电邮保护] 投资者关系: Anthony Zelen [受电邮保护] +1-778-388-5258 前瞻性陈述: 本新闻稿可能包含《1933年证券法》第27A 条和《1934年证券交易法》第21E 条含义内的“前瞻性声明”。这些报表涉及未来事件或未来业绩。并非纯粹历史的陈述是前瞻性陈述,包括任何有关信仰、计划、前景、预期或未来意图的陈述,包括“预期”、“成为”、“客观”、“可能”、“将”、“可能”、“应该”、“能够”、“打算”、“预期”、“相信”、“估计”、“预测”等词语或短语。“潜力”、“计划”、“旨在”、“项目”、“继续”或类似表达暗示未来结果或其负面或类似变化。该等前瞻性陈述包括但不限于,该公司将能够与 CGA 订立最终合资协议,该合资企业将成功,该合资企业将成功出售拟议的天然健康血红素衍生的 CBD 输液化妆品品牌亚洲人寿在中国各地,香港和亚洲.我们还面临着各种额外的风险,如我们的 SEC 文件中所描述的 www.SEC.gov 。 前瞻性陈述基于管理层目前的预期,可能与实际结果存在重大差异。此外,该等前瞻性陈述存在可能对我们的业务、经营业绩、财务状况及股价造成负面影响的风险及不明朗因素。 除法律要求外,我们明确声明不承担任何义务或承诺公开发布本协议所载任何前瞻性声明的任何更新或修订,以反映我们预期的任何变化或任何此类声明所依据的事件、条件或情况的任何变化。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文